169 related articles for article (PubMed ID: 30240472)
1. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C.
Weidner P; Boettche D; Zimmerer T; Burgermeister E; Teufel A; Ebert MPA; Antoni C
J Gastrointestin Liver Dis; 2018 Sep; 27(3):281-289. PubMed ID: 30240472
[TBL] [Abstract][Full Text] [Related]
2. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
3. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
5. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
6. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.
Drazilova S; Janicko M; Skladany L; Kristian P; Oltman M; Szantova M; Krkoska D; Mazuchova E; Piesecka L; Vahalova V; Rac M; Schreter I; Virag L; Koller T; Liptakova A; Ondrasova M; Jarcuska P
Can J Gastroenterol Hepatol; 2018; 2018():6095097. PubMed ID: 30402450
[TBL] [Abstract][Full Text] [Related]
7. Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus.
Qing S; Ji D; Li B; Li F; Wang Y; Niu X; Ling B; Meng Y; Lau G; Chen G
Ann Saudi Med; 2015; 35(4):293-7. PubMed ID: 26497709
[TBL] [Abstract][Full Text] [Related]
8. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Virus Clearance with Glucose Improvement and Factors Affecting the Glucose Control in Chronic Hepatitis C Patients.
Yuan M; Zhou J; Du L; Yan L; Tang H
Sci Rep; 2020 Feb; 10(1):1976. PubMed ID: 32029793
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
11. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
12. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control.
Andres J; Barros M; Arutunian M; Zhao H
J Manag Care Spec Pharm; 2020 Jun; 26(6):775-781. PubMed ID: 32463777
[TBL] [Abstract][Full Text] [Related]
14. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis.
Carnovale C; Pozzi M; Dassano A; D'Addio F; Gentili M; Magni C; Clementi E; Radice S; Fiorina P
Acta Diabetol; 2019 Mar; 56(3):341-354. PubMed ID: 30478781
[TBL] [Abstract][Full Text] [Related]
15. Expert opinion on managing chronic HCV infection in patients with type 2 diabetes mellitus.
Adinolfi LE; Jacobson I; Bondin M; Cacoub P
Antivir Ther; 2018; 23(Suppl 2):11-21. PubMed ID: 30451154
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of liver fibrosis using hepatic extracellular volume fraction by contrast-enhanced computed tomography before and after direct-acting antiviral therapy in patients with chronic hepatitis C infection: comparison with serological liver fibrosis markers.
Kanki A; Maeba K; Sotozono H; Yasokawa K; Higaki A; Yamamoto A; Tamada T
Br J Radiol; 2021 Nov; 94(1127):20210045. PubMed ID: 34586878
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
Abdel Alem S; Elsharkawy A; El Akel W; Abdelaziz AO; Salama RM; El-Sayed MH; El Kassas M; Anees M; Shedeed M; Abdelsalam F; Ziada DH; El Shazly Y; El-Serafy M; Waked I; Esmat G; Doss W
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):1009-1016. PubMed ID: 31418303
[No Abstract] [Full Text] [Related]
18. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
20. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
